Prostate Cancer UK welcomes new data from the STAMPEDE trial that clarifies there is no difference in the benefits offered by both treatments for men newly diagnosed with advanced disease, but now we want the option of earlier abiraterone made available to all men.
We handed in our ‘Don’t delay funding for vital new drugs and treatments’ petition to NHS England, to urge them to reconsider plans for a new spending cap on treatments. We received an incredible 29,006 signatures, but unfortunately the outcome wasn’t what we hoped for.
Thousands of men could be delayed or denied life-saving new drugs under plans to cap spending by NHS England, prompting "serious concern" and an online petition from leading health and care charities.
Today's Scottish green light for the chemotherapy drug means the same key treatments for advanced prostate cancer are now routinely available to eligible men in all the home nations.
Men living in the two home nations with prostate cancer that's spread to the bones will now be able to access the life-enhancing treatment on the NHS if they're unable to have chemotherapy, thanks to reversal of a decision in 2015.
Eligible men in Wales with newly diagnosed advanced prostate cancer will now be offered earlier access to docetaxel chemotherapy alongside hormone therapy. Combining these treatments has been shown to offer these men the possibility of an extra fifteen months of life on average.
After months of consultation and negotiation, the proposed changes to the Cancer Drugs Fund come into effect. But do they go far enough for men with prostate cancer?
Today’s approval of the hormone therapy, degarelix, by NICE expands on the decision made in 2014 to make it only available to those men who have already developed the symptoms of spinal cord compression. Now, men whose prostate cancer has spread to their spine and who could be at risk of this condition can also access this treatment.
Cabazitaxel chemotherapy has been rejected by the Scottish Medicines Consortium (SMC) for routine use on the NHS in Scotland, it has been announced today.
NICE's welcome decision follows a reappraisal involving new data and a price cut by the drug's manufacturer, but lengthy negotiations should be avoided in future.